Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 605 participants in total — 303 in Treatment A and 302 in Treatment B. The main thing the trial was measuring was **overall survival**, meaning how long participants lived from the time they were randomly assigned to a treatment group. The trial also tracked several secondary measures, including how many participants' tumours shrank or disappeared (called the objective response rate), how many participants had their disease stay stable or improve (called the disease control rate), and how long participants went without their disease getting worse (called progression-free survival). The reported data shows that for the primary measure — overall survival — the median time participants in Treatment A lived was approximately 18.1 months, compared with approximately 14.1 months for those in Treatment B. (Median means the middle value — half of participants lived longer than this, and half lived shorter.) For progression-free survival, the reported median was about 6.8 months for Treatment A and 7.2 months for Treatment B. The reported data shows that approximately 39.3% of participants in Treatment A and 44.4% in Treatment B had their tumours shrink or disappear. For disease control — which includes tumours that shrank, disappeared, or stayed stable — the reported figures were approximately 76.6% for Treatment A and 85.8% for Treatment B. The trial also looked at these survival figures broken down by a biological marker called PD-L1 expression (a protein measured on tumour cells), with reported median overall survival figures ranging from roughly 13 to 18 months across both groups and both expression levels. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41734361) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Mesothelioma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 18 years old (male or female)
- You must have been diagnosed with pleural malignant mesothelioma (a type of cancer affecting the lining of the lungs) that cannot be treated with surgery to cure it
- You must be well enough to carry out everyday activities with little or no limitation (confirm with trial site for exact fitness level required)
- A sample of your tumor tissue must be available for testing
- Your recent blood test results must meet certain health requirements (confirm with trial site)
Who may not be able to join:
- You cannot join if your mesothelioma started in the abdomen, around the heart, or in certain other locations rather than the lining of the lungs
- You cannot join if you have already received chemotherapy treatment for your mesothelioma
- You cannot join if you have previously been treated with certain types of immunotherapy drugs (a group of medicines that work by targeting the immune system)
- You cannot join if you have had another type of cancer in the past, unless you have been completely free of that cancer for at least 3 years
- You cannot join if you have cancer that has spread to your brain or spinal cord and is not currently being treated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.